Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Twelve healthy young males were examined in a randomized, controlled, double-blinded, single-day, crossover trial to evaluate the effects of 2 hours GLP-1 infusion on kidney functions.

Why It Was Studied

Glucagon-like peptide-1 (GLP-1) is an incretin hormone with multiple actions in addition to control of glucose homeostasis.

GLP-1 is known to cause natriuresis in humans, but the effects on basic renal physiology are still partly unknown.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Glucagon.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Glomerular filtration rate (GFR) and renal plasma flow (RPF) were assessed with (51)Cr-EDTA and (123)I-hippuran, respectively, using a constant infusion renal clearance technique based on timed urine sampling.

What Was Measured

PubMed files the paper under topics including Glomerular Filtration Rate, Glucagon-Like Peptide 1, Health, Hemodynamics, Kidney, Regional Blood Flow and Renin-Angiotensin System.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page, all human trials.